Compliments of Pharmavoice
Total Page:16
File Type:pdf, Size:1020Kb
INNOVATIVE COMPANIES Celebrating INNOVATION From animators to 3D tissue bioprocessing to innovator incubators to lab testing companies to clinical trial innovators to communication disrupters, these companies are changing the healthcare landscape. pening at major nonprofit institutions, such as to each patient’s genetic analysis to help them • • • the Multiple Myeloma Research Foundation’s learn how patients respond to therapies. in no va tion CoMMpass Study, launched in 2011 as the Another example of cross collaboration is the action or process of innovating. first of its kind in myeloma. The collaboration the National Institutes of Health’s Brain Re- includes world-class researchers in more than search through Advancing Innovative Neuro- • a new method, idea, product, etc. 90 institutions. A “dream team” of cancer technologies (BRAIN) Initiative, which is part specialists is helping researchers gain access of a Presidential focus aimed at revolutionizing hen this special issue was con- ceived, the idea was to shine a W light on the innovators and in- novations that are changing the life-sciences Innovative Leaders industry. We issued a call to action to our readers to identify the companies that are Now in its fifth year, IDEA Pharma’s (ideapharma. first hepatitis C combination pill, Harvoni; the changing the paradigm and the products, com) Productive Innovation Index (PII) celebrates continued return on investment for Stribild; tools, technologies, processes, etc. that are the top 30 pharmaceutical companies most ef- achieving FDA approval and breakthrough making a difference in the lives of patients. fective at developing and commercializing new designation for Zybelig, and obtaining CDC We were overwhelmed by the responses; at medicines — bringing innovationsPharmaVOICE to market backing for Truvada. This saw the company the same time we are very much aware that the successfully. The index can be summarized by the knock Novartis down to rank third. companies and products featured in this issue question: if you gave the same molecule to two Despite its move, Novartis has remained only scratch the surface of the innovations that different companiesof in early phase, which would in the top three in recognition for the contin- are taking place everyday in every sector of make the best of it? ued growth from its core assets Afinitor, Ta- healthcare. Based on an objective, rolling analysis of signa, Zortress, and Gilenya, and contributions For example, just last month Johnson each company’s performance, between 2009 and from its industry-leading late-stage pipeline. & Johnson Innovation LLC announced the 2014, Johnson & Johnson (J&J) has continued Supporting this were a number of key approv- opening of JLABS @South San Francisco, a to demonstrate its leadership in pharmaceuti- als in 2014, including Zykadia for metastatic 30,000-square foot incubator that can ac- cal product commercialization. They remain ce- lung cancer, Xolair for hives, and Cosentyx commodate up to 50 startups from across mented in first place for the third year running, for psoriasis to name a few. Bexsero also had the healthcare spectrum including biotech, despite a significant shift in companies moving a good year with a breakthrough designa- pharmaceutical, medical device, consumer, into the top 10. tion, winning Prix Galien and FDA approval. and digital health. The first resident startups With eight of its drugs hitting double-digit What pegged Novartis back was the refusal have been selected, including the winners of growth across five disease franchises, J&J’s world- for serelaxin in heart failure, and pulling the the Johnson & Johnson Innovation, JLABS wide pharmaceutical sales increased by 14.9%, Tasigna EMA application for Philadelphia chro- Quick Fire Challenge, which was designed to with the star performer being its hepatitis C mosome positive-CML. recognize the most promising new, early-stage combination drug Olysio/Sovriad, reaching over Other companies that made significant innovation companies and award them with $2 billion in sales in 12 months. This growth was moves into the top 10 were Biogen, Amgen, the use of a bench and access to the JLABS @ bolstered further with successful launches for and Celgene – the latter was the second big- SSF community. Invokana, Imbruvica, and Zytiga, which helped to gest climber into the upper echelons, moving J&J is not the only major pharma company strengthen its position in the ranking alongside from 16th to take 8th place, for successfully that is fielding incubator type facilities to new approvals for Invega Sustenna and Rezolsta. expanding its reach from oncology and hav- encourage openCompliments collaboration. Bayer has also Notably, the biggest climber — moving up ing an immediate impact in the immunology invested in an incubator, the CoLaborator in from 18th to take second place — is Gilead Sci- arena. San Francisco, to offer biotechs the lab space, ences for its standout performance in launching The PII looks beyond revenue figures and shared facilities, and resources necessary for blockbuster drug Sovaldi, pulling in $10 billion raw approval rates and assesses companies discovery. Merck established the California in revenue in just one year, one of the industry’s based on a range of factors, including speed Institute for Biomedical Research (Calibr) and most successful launches ever. Cited as one to to market, attrition rate across phases — in (c) PharmaLinx LLC. Rights do not include promotional use. For distribution or printing rights, contact [email protected] Pfizer initiated The Pfizer Incubator and The watch in last year’s Index, Gilead’s undeniable particular Phase III, reimbursement rates, regu- Centers for Therapeutic Innovation (CTI). rise was also reinforced by the launch of the latory approvals, and analyst rankings. Additionally, open collaboration is hap- 12 April 2015 PharmaVOICE INNOVATIVE COMPANIES our understanding of the human brain. By “innovation is work,” business executives are deliver the needed level of innovation. It seems accelerating the development and application focusing less on informal processes that pro- as though new thinking to elevate value and of innovative technologies, researchers will be duce incremental improvements to internal launch dramatic growth opportunities is in able to produce a revolutionary new dynamic operations and more on formal innovation the DNA of the enterprise, with every single picture of the brain that, for the first time, approaches that generate “breakthrough” and employee committed to innovation. shows how individual cells and complex neural “radical” innovation. Insigniam executives offer several best circuits interact in both time and space. Long In PWC’s latest innovation study, 69% practices to create an innovative culture, in- desired by researchers seeking new ways to of 1,757 senior executives contend having a cluding: inoculate against the corporate im- treat, cure, and even prevent brain disorders, well-defined innovation process is important mune system; less corporate gravity; corrected this picture will fill major gaps in our current to establishing a culture of innovation. This corporate myopia; greater innovation thrust; knowledge and provide unprecedented oppor- rigor is necessary to improve the chances of creativity, capability, and capacity; and effec- tunities for exploring exactly how the brain innovation success. To make headline-worthy tive execution. enables the human body to record, process, innovations happen, a significant percentage There is no doubt that big data in all its utilize, store, and retrieve vast quantities of of companies are looking to new innovation petrabytes is significantly driving innovations information, all at the speed of thought. models such as open innovation (collabora- across every sector. Companies such as GE and We know that innovation is happening in tion with outside partners), design thinking Siemens are breaking barriers and moving the big pharma companies, at startup biotechs, at (looking at the need from an anthropologist’s needle in significant ways. And we can’t forget med/device companies, in hospital systems, perspective), corporate venturing (investing to note IBM and Watson, the supercomputer and in every type of company that supports the in startups), and incubators (small groups of that is using big data analytics to address vast life-sciences industry. intrapreneurs that use rapid prototyping). healthcare’s hierarchy. Nontraditional healthcare companies such The consulting company Insigniam contends Over the past 15 years, PharmaVOICE has as Google and Microsoft are collaborating that innovations can be small or large, from incre- been excited to share the insights of innovators with brand-name pharma companies. Univer- mental step-changes to outright breakthroughs. and provide visibility to the innovations that sities are partnering with emerging startups. We agree, as evidenced by the innovations fea- are changing the industry. And, in the past Healthcare advertising agencies are teaming tured in this issue. Some are outright audacious two years we have dedicated a special depart- up with software developers. Clinical service in their vision, while others provide incremental, ment each month — Innovator’s Corner — to providers of all types are taking to the cloud. yet vital, changes to the system. spotlight companies that are changing the There seems to be no limit to the lengths for- Executives at Insigniam add that success- status quo. (See Letter